Ketamine Mechanism of Action for Treatment-Resistant Depression: The BDNF/mTOR Story

If you've arrived here, you've probably already tried two or more antidepressants. You know the SSRI story. You want to know what's different about this one, specifically at the mechanism level, because you've earned the right to be skeptical of anything else marketed as a breakthrough.

This is the mechanism article. It's longer and more technical than our plain-language explainer. The focus is narrow: what ketamine is actually doing at the synaptic level that allows it to produce antidepressant response in patients for whom serotonin-modulating drugs haven't.

Why SSRIs don't always work

Depression isn't one disease. The term groups together a set of clinical pictures that share symptoms — persistent low mood, anhedonia, sleep and appetite changes, cognitive slowing — but that can arise from very different underlying neurobiology. Current psychiatric practice starts with SSRIs or SNRIs because they work for a substantial fraction of patients, they're well-tolerated at a population level, and we don't yet have good biomarkers to predict which patient will respond to which mechanism.

Roughly 30-40% of patients with major depressive disorder don't respond adequately to first-line antidepressants. That's treatment-resistant depression. The current thinking, based on a growing body of neuroimaging and molecular work, is that TRD involves more than just serotonin signaling — glutamatergic dysregulation, HPA-axis dysfunction, and deficits in synaptic plasticity all appear to play larger roles than they do in SSRI-responsive depression.

This is why a drug that acts on a completely different pathway (glutamate, synaptogenesis, BDNF) can produce response in patients who've failed multiple serotonergic agents. The tool is matching a different part of the problem.

The molecular cascade, in order

Ketamine's antidepressant mechanism involves several linked events that happen on different timescales. Here they are in order.

1. NMDA receptor blockade on GABAergic interneurons (minutes)

Ketamine binds to NMDA (N-methyl-D-aspartate) glutamate receptors, preferentially blocking them on inhibitory GABAergic interneurons in the prefrontal cortex. These interneurons normally dampen the activity of nearby pyramidal neurons. Blocking their NMDA receptors disinhibits the pyramidal neurons — in plain terms, the brakes come off.

This is the "disinhibition hypothesis," developed primarily by Ronald Duman's lab at Yale and supported by subsequent work from multiple groups. The key insight is that ketamine's therapeutic effect doesn't come from blocking glutamate signaling — it comes from unblocking it, by removing the inhibition that was suppressing it.

2. Glutamate surge in prefrontal cortex (30-60 minutes)

Once the inhibitory brake is released, pyramidal neurons fire more actively, releasing glutamate into synapses across prefrontal cortex. This glutamate surge is measurable on MR spectroscopy and correlates with the onset of antidepressant response. Patients whose prefrontal glutamate doesn't rise tend not to respond; patients whose glutamate rises robustly tend to respond better and sooner.

Crucially, the glutamate surge activates AMPA receptors (a different class of glutamate receptor from NMDA). AMPA activation is what drives the downstream cascade. Blocking AMPA with pharmacological inhibitors abolishes ketamine's antidepressant effect in preclinical models. This is one of the cleanest mechanism proofs we have.

3. BDNF release and TrkB activation (hours)

The AMPA-driven pyramidal activity triggers release of BDNF (brain-derived neurotrophic factor), a neurotrophin that binds tropomyosin receptor kinase B (TrkB) on dendrites. BDNF-TrkB signaling is the master regulator of synaptic growth and remodeling in the adult brain. Chronic stress and depression suppress BDNF signaling; ketamine acutely restores and amplifies it.

This step is where the treatment effect becomes lasting. A transient block of NMDA receptors produces, several steps downstream, a sustained increase in the growth signal for new synaptic connections.

4. mTORC1 activation and protein synthesis (hours)

TrkB activation engages the mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway, which controls protein synthesis in neurons. mTORC1 turns on the translation of synaptic proteins — specifically the proteins needed to build and strengthen new dendritic spines. Rapamycin, an mTORC1 inhibitor, blocks ketamine's antidepressant effect in animal models, which is another strong piece of mechanism evidence.

The mTORC1 activation is what translates the transient neurochemical event into durable structural change.

5. Synaptogenesis and spine density recovery (24-72 hours)

The proteins produced downstream of mTORC1 are used to build new dendritic spines and strengthen existing ones. Post-mortem and neuroimaging studies consistently show that chronic stress and depression reduce dendritic spine density in prefrontal cortex and hippocampus. Ketamine administration reverses this — new spines form, spine density recovers, and the architectural deficit that characterizes depressed brains begins to repair.

This is the part that's genuinely remarkable. Most psychiatric medications work on transmitter balance; ketamine works by regrowing the structural connections between neurons. The mechanism is more akin to what BDNF-driven processes do after injury or during learning.

6. Behavioral and mood response (hours to days)

The molecular cascade above produces measurable antidepressant effect within hours — often faster than patients expect. Formal rating-scale response (MADRS, HAM-D) typically shows significant reduction at 24 hours post-infusion in clinical trials. The behavioral effect is downstream of and proportional to the synaptic changes.

Why this mechanism helps with TRD specifically

Three properties of this mechanism are directly relevant to treatment-resistant cases.

It bypasses serotonin entirely. If a patient's depression doesn't respond to serotonergic manipulation, ketamine reaches for a different lever. There's no reason to expect that five failed SSRI trials should predict failure on a glutamatergic intervention.

It addresses the structural deficit. The dendritic-spine pruning seen in chronic depression is a maintenance problem: the brain can't get out of the depressed state partly because the physical connectivity that would support a healthier state has atrophied. Ketamine drives regrowth of that connectivity. SSRIs don't do this — their effect is almost entirely on neurotransmitter balance.

It's rapid. For severe depression, especially depression with suicidal ideation, a six-week delay for an SSRI to maybe work is often not acceptable. Ketamine's hours-to-days response window is clinically meaningful, not just convenient.

Why the effect isn't permanent from a single session

A single ketamine session produces a burst of BDNF signaling, a wave of mTORC1 activation, and a period of spine regrowth. But the brain's normal plasticity mechanisms — pruning, stabilization, adjustment to ongoing input — continue operating. Without reinforcement, the newly grown spines can be pruned again within weeks if the usage patterns that drove the depression (rumination, social isolation, inactivity, poor sleep) haven't changed.

This is why:

• Response from single sessions typically lasts 1-2 weeks.
• Induction courses (6 sessions over 4-6 weeks) produce more durable response than single sessions.
• Patients who combine ketamine with psychotherapy, sleep restoration, exercise, and real integration work do substantially better than patients who treat sessions as isolated drug events.

The neuroplasticity window is a tool, not a cure. What you do inside it determines what persists.

How ketamine differs from other rapid-acting options

Spravato (esketamine). Same general mechanism (NMDA antagonism → disinhibition → BDNF cascade), delivered as intranasal S-ketamine under a REMS program. FDA-approved for TRD. See our R vs. S ketamine piece for the enantiomer specifics.

TMS (transcranial magnetic stimulation). Induces activity in prefrontal circuits through an entirely different mechanism — electromagnetic stimulation of cortical neurons. Effective for some TRD patients; produces response over weeks rather than hours.

ECT (electroconvulsive therapy). Still the gold standard for severe TRD, especially with psychotic features. Produces strong and rapid response. The side-effect profile (cognitive effects) is the main reason patients prefer alternatives when available.

Next-generation NMDA modulators. Compounds like aptinurin and members of the rapastinel family are in various stages of development and aim to preserve the antidepressant effect while minimizing the dissociative experience. None currently FDA-approved.

Response rates and what to expect

Meta-analyses of ketamine for TRD consistently report response rates (defined as ≥50% reduction in depression scores) in the 60-75% range within 24-72 hours of a single dose. Remission rates (full symptom resolution) are lower, in the 30-50% range. Response rates with a proper induction course (6 sessions) and integration work are higher.

These numbers are for TRD populations specifically — patients who have failed at least two prior adequate antidepressant trials. Response rates in SSRI-naive depression are similar to or somewhat higher than with SSRIs, but ketamine is rarely first-line in that population; the drug makes most clinical sense when other options have been exhausted.

Related reading

• Why ketamine works when 2+ antidepressants have failed — the clinical picture behind the neurobiology.
• Understanding treatment-resistant depression — diagnostic context.
• The integration process — how to actually use the neuroplasticity window ketamine opens.
• Ketamine-assisted psychotherapy — the structured version of integration work.

Ready to start?

If you've been through several antidepressants without adequate response and this mechanism-level explanation fits your clinical picture, the five-minute eligibility check will tell you whether our at-home program is a reasonable next step.

Discreet Ketamine provides at-home ketamine therapy supervised by Dr. Ben Soffer, a board-certified physician, to residents of Florida and New Jersey. Compounded racemic ketamine is prescribed off-label for depression, anxiety, PTSD, and chronic pain; it is not FDA-approved for these indications.